To examine whether serotonin (5-HT) related genetic variants moderate the effects of selective serotonin reuptake inhibitors (SSRIs) on skeletal outcomes.
Methods:
Trabecular bone mineral density (BMD) at the radius, lumbar spine (LS) BMD, total body less head (TBLH) bone mineral content (BMC) and markers of bone metabolism (osteocalcin, C-terminal telopeptide of type I collagen [CTX-1], and bone specific alkaline phosphatase to CTX-1 ratio) were examined in an observational study, enrolling 15- to 20-year-old participants, unmedicated or within a month of SSRI initiation. Variants in HTR1A (rs6295), HTR1B (rs6296), HTR1D (rs6300), HTR2A (rs6311 and rs6314), HTR2B (rs6736017), and the serotonin transporter intron 2 variable number tandem repeat (STin2 VNTR) were genotyped. Linear mixed-effects regression analysis examined associations between SSRI use, genetic variants, and skeletal outcomes.
Results:
After adjusting for relevant covariates, rs6295 CC and GC genotypes in 262 participants (60% female, mean ± SD age = 18.9 ± 1.6 years) were significantly associated with higher LS BMD compared to the GG genotype. Rs6311 GG SSRI users had greater LS BMD compared to nonusers (β = 0.18, p = <0.0001). Female SSRI users with the combination of rs6295 CC+GC and rs6311 GG genotypes had greater LS BMD than female SSRI nonusers (β = 0.29, p < 0.0001). SSRI users with the rs6295 GG genotype had higher trabecular BMD compared to nonusers (β = 3.60, p = 0.05). No significant interactions were found for TBLH BMC or bone turnover markers. After correcting for multiple comparisons, none of the results retained significance.
Conclusions:
In older adolescents and young adults, HTR1A (rs6295) and HTR2A (rs6311) variants may moderate the effect of SSRIs on BMD. Sex differences may exist and require further examination. Further research with larger sample sizes is needed to confirm our preliminary findings.
Clinical Trial Registration:
clinicaltrials.gov NCT02147184.
Get full access to this article
View all access options for this article.
References
1.
AkE, BulutSD, BulutS, et al.Evaluation of the effect of selective serotonin reuptake inhibitors on bone mineral density: An observational cross-sectional study. Osteoporos Int, 2015; 26(1):273–279; doi: 10.1007/s00198-014-2859-2
2.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). American Psychiatric Association: Washington, DC; 2000.
3.
BaldingerP, KrausC, Rami-MarkC, et al.Interaction between 5-HTTLPR and 5-HT1B genotype status enhances cerebral 5-HT1A receptor binding. Neuroimage, 2015; 111:505–512; doi: 10.1016/j.neuroimage.2015.01.049
4.
BarreraTL, NortonPJ. Quality of life impairment in generalized anxiety disorder, social phobia, and panic disorder. J Anxiety Disord, 2009; 23(8):1086–1090; doi: 10.1016/j.janxdis.2009.07.011
5.
BeckAT.Depression: Clinical, Experimental, and Theoretical Aspects. Hoeber Medical Division, Harper & Row: New York; 1967.
6.
BeckAT, EpsteinN, BrownG, et al.An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol, 1988; 56(6):893–897; doi: 10.1037/0022-006x.56.6.893
7.
BlasiG, De VirgilioC, PapazachariasA, et al.Converging evidence for the association of functional genetic variation in the serotonin receptor 2a gene with prefrontal function and olanzapine treatment. JAMA Psychiatry, 2013; 70(9):921–930; doi: 10.1001/jamapsychiatry.2013.1378
8.
BliziotesM, EshlemanA, Burt-PichatB, et al.Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone, 2006; 39(6):1313–1321; doi: 10.1016/j.bone.2006.06.009
9.
BliziotesMM, EshlemanAJ, ZhangXW, et al.Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake. Bone, 2001; 29(5):477–486; doi: 10.1016/s8756-3282(01)00593-2
10.
CalargeCA, ButcherBD, BurnsTL, et al.Major depressive disorder and bone mass in adolescents and young adults. J Bone Miner Res, 2014; 29(10):2230–2237; doi: 10.1002/jbmr.2249
11.
CalargeCA, EllingrodVL, ZimmermanB, et al.Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: A reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry, 2011; 72(12):1685–1690; doi: 10.4088/JCP.10m06198
12.
CalargeCA, MillsJA, JanzKF, et al.Body composition in adolescents during treatment with selective serotonin reuptake inhibitors. Pediatrics, 2017a;140(1); doi: 10.1542/peds.2016-3943
13.
CalargeCA, MillsJA, JanzKF, et al.The effect of depression, generalized anxiety, and selective serotonin reuptake inhibitors on change in bone metabolism in adolescents and emerging adults. J Bone Miner Res, 2017b;32(12):2367–2374; doi: 10.1002/jbmr.3238
14.
Centers for Disease Control and Prevention. Antidepressant Use Among Persons Aged 12 and Over: United States, 2011–2014. 2017. Available from: https://www.cdc.gov/nchs/products/databriefs/db283.htm [Last accessed: July16, 2023].
15.
Centers for Disease Control and Prevention. Antidepressant Use Among Adults: United States, 2015–2018. 2020. Available from: https://www.cdc.gov/nchs/products/databriefs/db377.htm#:∼:text=During%202015%E2%80%932018%2C%2013.2%25%20of%20adults%20used%20antidepressants%20in,those%20aged%2060%20and%20over [Last accessed: July16, 2023].
16.
CoutinhoAM, SousaI, MartinsM, et al.Evidence for epistasis between SLC6A4 and ITGB3 in autism etiology and in the determination of platelet serotonin levels. Hum Genet, 2007; 121(2):243–256; doi: 10.1007/s00439-006-0301-3
17.
DaiSQ, YuLP, ShiX, et al.Serotonin regulates osteoblast proliferation and function in vitro. Braz J Med Biol Res, 2014; 47(9):759–765; doi: 10.1590/1414-431x20143565
18.
de LijsterJM, DielemanGC, UtensE, et al.Social and academic functioning in adolescents with anxiety disorders: A systematic review. J Affect Disord, 2018; 230:108–117; doi: 10.1016/j.jad.2018.01.008
19.
Deumic ShultzE, MillsJA, EllingrodVL, et al.Sexual functioning in adolescents with major depressive disorder: A prospective study. J Clin Psychiatry, 2021; 82(6); doi: 10.4088/JCP.21m13892
20.
DonaldsonZR, le FrancoisB, SantosTL, et al.The functional serotonin 1a receptor promoter polymorphism, rs6295, is associated with psychiatric illness and differences in transcription. Transl Psychiatry, 2016; 6(3):e746; doi: 10.1038/tp.2015.226
21.
DuncanEL, BrownMA. Genetic determinants of bone density and fracture risk—State of the art and future directions. J Clin Endocrinol Metab, 2010; 95(6):2576–2587; doi: 10.1210/jc.2009-2406
22.
FeuerAJ, DemmerRT, ThaiA, et al.Use of selective serotonin reuptake inhibitors and bone mass in adolescents: An NHANES study. Bone, 2015; 78:28–33; doi: 10.1016/j.bone.2015.04.042
23.
FraherD, HodgeJM, CollierFM, et al.Citalopram and sertraline exposure compromises embryonic bone development. Mol Psychiatry, 2016; 21(5):656–664; doi: 10.1038/mp.2015.135
24.
GarfieldLD, MullerDJ, KennedyJL, et al.Genetic variation in the serotonin transporter and HTR1B receptor predicts reduced bone formation during serotonin reuptake inhibitor treatment in older adults. World J Biol Psychiatry, 2014; 15(5):404–410; doi: 10.3109/15622975.2013.832380
25.
GizerIR, FicksC, WaldmanID. Candidate gene studies of ADHD: A meta-analytic review. Hum Genet, 2009; 126(1):51–90; doi: 10.1007/s00439-009-0694-x
26.
GolubMS, BulleriAM, HogrefeCE, et al.Bone growth in juvenile rhesus monkeys is influenced by 5HTTLPR polymorphisms and interactions between 5HTTLPR polymorphisms and fluoxetine. Bone, 2015; 79:162–169; doi: 10.1016/j.bone.2015.05.042
27.
GoodwinRD, DierkerLC, WuM, et al. Trends in U.S. Depression Prevalence from 2015 to 2020: The widening treatment gap. Am J Prev Med, 2022; doi: 10.1016/j.amepre.2022.05.014
28.
GustafssonBI, ThommesenL, StunesAK, et al.Serotonin and fluoxetine modulate bone cell function in vitro. J Cell Biochem, 2006; 98(1):139–151; doi: 10.1002/jcb.20734
HuangJH, ChangHA, FangWH, et al.Serotonin receptor 1A promoter polymorphism, rs6295, modulates human anxiety levels via altering parasympathetic nervous activity. Acta Psychiatr Scand, 2018; 137(3):263–272; doi: 10.1111/acps.12853
31.
HuangY, ZhangX, GaoJ, et al.Association of STin2 VNTR polymorphism of serotonin transporter gene with lifelong premature ejaculation: A case-control study in Han Chinese subjects. Med Sci Monit, 2016; 22:3588–3594; doi: 10.1265/9/msm.897720
32.
HuangYY, GrailheR, ArangoV, et al.Relationship of psychopathology to the human serotonin1B genotype and receptor binding kinetics in postmortem brain tissue. Neuropsychopharmacology, 1999; 21(2):238–246; doi: 10.1016/s0893-133x(99)00030-5
33.
JanzKF, LutuchyEM, WentheP, et al.Measuring activity in children and adolescents using self-report: PAQ-C and PAQ-A. Med Sci Sports Exerc, 2008; 40(4):767–772; doi: 10.1249/MSS.0b013e3181620ed1
34.
JinC, XuW, YuanJ, et al.Meta-analysis of association between the -1438A/G (rs6311) polymorphism of the serotonin 2A receptor gene and major depressive disorder. Neurol Res, 2013; 35(1):7–14; doi: 10.1179/1743132812y.0000000111
35.
KaoWT, ChangCL, LungFW. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial. J Affect Disord, 2018; 238:597–608; doi: 10.1016/j.jad.2018.06.035
36.
KesslerRC, ChiuWT, DemlerO, et al.Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 2005; 62(6):617–627; doi: 10.1001/archpsyc.62.6.617
37.
KouraSM, SalamaM, El-HussinyM, et al.Fluoxetine induces direct inhibitory effects on mesenchymal stem cell-derived osteoprogenitor cells independent of serotonin concentration. Mol Med Rep, 2019; 19(4):2611–2619; doi: 10.3892/mmr.2019.9924
38.
LacosteJ, LamyS, RamozN, et al.A positive association between a polymorphism in the HTR2B gene and cocaine-crack in a French Afro-Caribbean population. World J Biol Psychiatry, 2020; 21(10):784–789; doi: 10.1080/15622975.2018.1563721
39.
LavoieB, LianJB, MaweGM. Regulation of bone metabolism by serotonin. Adv Exp Med Biol, 2017; 1033:35–46; doi: 10.1007/978-3-319-66653-2_3
40.
Lebrun-HarrisLA, GhandourRM, KoganMD, et al.Five-year trends in US Children's Health and well-being, 2016–2020. JAMA Pediatr, 2022; 176(7):e220056; doi: 10.1001/jamapediatrics.2022.0056
41.
LeeEJ, OhMS, KimJS, et al.Serotonin transporter gene polymorphisms may be associated with poststroke neurological recovery after escitalopram use. J Neurol Neurosurg Psychiatry, 2018; 89(3):271–276; doi: 10.1136/jnnp-2017-316882
MarinovaZ, MonoranuCM, FetzS, et al.Region-specific regulation of the serotonin 2A receptor expression in development and ageing in post mortem human brain. Neuropathol Appl Neurobiol, 2015; 41(4):520–532; doi: 10.1111/nan.12167
44.
MekliK, PaytonA, MiyajimaF, et al.The HTR1A and HTR1B receptor genes influence stress-related information processing. Eur Neuropsychopharmacol, 2011; 21(1):129–139; doi: 10.1016/j.euroneuro.2010.06.013
45.
MouraC, BernatskyS, AbrahamowiczM, et al.Antidepressant use and 10-year incident fracture risk: The population-based Canadian Multicentre Osteoporosis Study (CaMoS). Osteoporos Int, 2014; 25(5):1473–1481; doi: 10.1007/s00198-014-2649-x
46.
MyersRL, AireyDC, ManierDH, et al.Polymorphisms in the regulatory region of the human serotonin 5-HT2A receptor gene (HTR2A) influence gene expression. Biol Psychiatry, 2007; 61(2):167–173; doi: 10.1016/j.biopsych.2005.12.018
47.
OgdenC, KuczmarskiR, FlegalK, et al.Centers for Disease Control and Prevention 2000 Growth Charts for the United States: Improvements to the 1977 National Center for Health Statistics Version. J Pediatr, 2002; 109(1):45–60.
48.
ParsonsMJ, D'SouzaUM, ArranzMJ, et al.The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol Psychiatry, 2004; 56(6):406–410; doi: 10.1016/j.biopsych.2004.06.020
49.
Pizzo de CastroMR, Vargas NunesSO, GuembarovskiRL, et al.STin2 VNTR polymorphism is associated with comorbid tobacco use and mood disorders. J Affect Disord, 2015; 172:347–354; doi: 10.1016/j.jad.2014.10.023
50.
RushAJ, GullionCM, BascoMR, et al.The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med, 1996; 26(3):477–486; doi: 10.1017/s0033291700035558
51.
SeifertCF, WiltroutTR. Calcaneal bone mineral density in young adults prescribed selective serotonin reuptake inhibitors. Clin Ther, 2013; 35(9):1412–1417; doi: 10.1016/j.clinthera.2013.07.423
52.
ShafferD, FisherP, LucasCP, et al.NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): Description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry, 2000; 39(1):28–38; doi: 10.1097/00004583-200001000-00014
53.
SmithRM, PappAC, WebbA, et al.Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. Biol Psychiatry, 2013; 73(6):546–554; doi: 10.1016/j.biopsych.2012.09.028
54.
SpiesM, NasserA, OzenneB, et al.Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin-2A receptor levels. Hum Brain Mapp, 2020; 41(16):4518–4528; doi: 10.1002/hbm.25138
55.
StutzmanDL.Long-term use of antidepressants, mood stabilizers, and antipsychotics in pediatric patients with a focus on appropriate deprescribing. Ment Health Clin, 2021; 11(6):320–333; doi: 10.9740/mhc.2021.11.320
56.
TsapakisEM, GamieZ, TranGT, et al.The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry, 2012; 27(3):156–169; doi: 10.1016/j.eurpsy.2010.10.006
57.
VerbekeG.Linear Mixed Models for Longitudinal Data (Springer Series in Statistics). Springer: New York, NY; 2009.
58.
WeberDR, MooreRH, LeonardMB, et al.Fat and lean BMI reference curves in children and adolescents and their utility in identifying excess adiposity compared with BMI and percentage body fat. Am J Clin Nutr, 2013; 98(1):49–56; doi: 10.3945/ajcn.112.053611
59.
WilkieMJ, SmithG, DayRK, et al.Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy. Pharmacogenomics J, 2009; 9(1):61–70; doi: 10.1038/sj.tpj.6500491
60.
WuX, YaoJ, DingM, et al.5-HT1A receptor (HTR1A) 5′ region haplotypes significantly affect protein expression in vitro. Neurosci Lett, 2017; 638:51–54; doi: 10.1016/j.neulet.2016.12.011
61.
XuZ, ZhangZ, ShiY, et al.Influence and interaction of genetic polymorphisms in the serotonin system and life stress on antidepressant drug response. J Psychopharmacol, 2012; 26(3):349–359; doi: 10.1177/0269881111414452
62.
ZemelBS, KalkwarfHJ, GilsanzV, et al.Revised reference curves for bone mineral content and areal bone mineral density according to age and sex for black and non-black children: Results of the bone mineral density in childhood study. J Clin Endocrinol Metab, 2011; 96(10):3160–3169; doi: 10.1210/jc.2011-1111
63.
ZhaoX, HuangY, LiJ, et al.Association between the 5-HT1A receptor gene polymorphism (rs6295) and antidepressants: A meta-analysis. Int Clin Psychopharmacol, 2012; 27(6):314–320; doi: 10.1097/YIC.0b013e32835818bf
64.
ZhouC, FangL, ChenY, et al.Effect of selective serotonin reuptake inhibitors on bone mineral density: A systematic review and meta-analysis. Osteoporos Int, 2018; 29(6):1243–1251; doi: 10.1007/s00198-018-4413-0
65.
ZhuX, ZhengH. Factors influencing peak bone mass gain. Front Med, 2021; 15(1):53–69; doi: 10.1007/s11684-020-0748-y
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
